Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Promis Neurosciences Inc (PMN)

Promis Neurosciences Inc (PMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,852
  • Shares Outstanding, K 2,152
  • Annual Sales, $ 0 K
  • Annual Income, $ 2,780 K
  • EBIT $ -35 M
  • EBITDA $ -35 M
  • 60-Month Beta -0.05
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -4.22
  • Number of Estimates 1
  • High Estimate -4.22
  • Low Estimate -4.22
  • Prior Year -0.50
  • Growth Rate Est. (year over year) -744.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.51 +13.13%
on 12/01/25
9.42 -21.82%
on 12/16/25
+0.60 (+8.95%)
since 11/28/25
3-Month
6.27 +17.46%
on 11/28/25
15.13 -51.31%
on 10/07/25
-3.64 (-33.05%)
since 09/29/25
52-Week
6.27 +17.46%
on 11/28/25
39.75 -81.47%
on 07/21/25
-15.14 (-67.27%)
since 12/27/24

Most Recent Stories

More News
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term value inflection points, with blinded 6-month...

PMN : 7.36 (-3.85%)
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque  ProMIS on track to complete enrollment in PRECISE-AD trial...

PMN : 7.36 (-3.85%)
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Cross-trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-driven design of ProMIS’ PRECISE-AD trial ProMIS on track to leverage new...

PMN : 7.36 (-3.85%)
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease...

PMN : 7.36 (-3.85%)
ProMIS Neurosciences Announces Reverse Stock Split

Cambridge, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD)...

PMN : 7.36 (-3.85%)
ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Phase 1b trial in Alzheimer’s disease is over 85% enrolled: Cohorts 1 and 2 are fully enrolled PMN310 continues to demonstrate a favorable safety profile On track to report 6-month interim...

PMN : 7.36 (-3.85%)
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310 Cambridge, Massachusetts,...

PMN : 7.36 (-3.85%)
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics

/CNW/ -- USA News Group News Commentary –Today, Americans over 65 command $22,356 in annual healthcare spending per person versus just $4,217 for children[1],...

PMN : 7.36 (-3.85%)
SLDB : 5.69 (-2.57%)
QURE : 24.56 (-1.01%)
AVAI : 0.2910 (-0.51%)
HCWB : 1.2500 (-11.97%)
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics

USA News Group News Commentary

PMN : 7.36 (-3.85%)
QURE : 24.56 (-1.01%)
SLDB : 5.69 (-2.57%)
AVAI : 0.2910 (-0.51%)
HCWB : 1.2500 (-11.97%)
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310

Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level); No cases of amyloid-related imaging abnormalities (ARIA) observed to date; The trial, expected to...

PMN : 7.36 (-3.85%)

Business Summary

ProMIS Neurosciences Inc. is a development stage biotechnology company. It focused on discovering and developing medicine therapeutics to treat neurodegenerative diseases in particular Alzheimer's disease and amyotrophic lateral sclerosis. The company's product portfolio includes PMN310, PMN350, PMN330,...

See More

Key Turning Points

3rd Resistance Point 8.06
2nd Resistance Point 7.83
1st Resistance Point 7.60
Last Price 7.36
1st Support Level 7.14
2nd Support Level 6.91
3rd Support Level 6.68

See More

52-Week High 39.75
Fibonacci 61.8% 26.96
Fibonacci 50% 23.01
Fibonacci 38.2% 19.06
Last Price 7.36
52-Week Low 6.27

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar